



Tourette syndrome and chronic tic disorders

Psychoeducation for children, adults and families

Tamara Pringsheim MD FRCPC Neurology, Professor University of Calgary, President Tourette OCD Alberta Network



Objectives

1. To review the clinical phenomenology and diagnostic criteria for tic disorders
2. To discuss the natural history of tic disorders
3. To describe the epidemiology of tic disorders and common comorbid disorders
4. To review recommendations on assessment and treatment of tic disorders

Clinical Phenomenology and Diagnostic Criteria



Tics: Definition

A sudden, rapid, recurrent, non-rhythmic motor movement or vocalization

Fragments of normal motor actions or vocalizations that are misplaced in context

Motor Tics


Simple Motor Tics

- Sudden, brief, meaningless movements
 - Eye blinking
 - Eye movements
 - Grimacing
 - Nose twitching
 - Mouth movements
 - Head jerks
 - Shoulder shrugs
 - Abdominal tensing

Complex Motor Tics

- Slower, longer, more “purposeful” movements
- Rarely seen in absence of simple motor tics
 - Touching objects or self
 - Gestures with hands
 - Dystonic postures
 - Obscene gestures (copropraxia)

Prevalence of motor tics by type/location



** simple tics predominate*

Vocal Tics


Simple Vocal Tics

- Sudden, meaningless sounds or noises
 - Throat clearing
 - Coughing
 - Sniffing
 - Screeching
 - Barking
 - Grunting

Complex Vocal Tics

- Syllables, words, phrases or statements
- Odd patterns of speech
 - Sudden changes in rate, rhythm, volume
- Echolalia
- Obscene, inappropriate and aggressive words or statements (coprolalia)

Prevalence of vocal tics by type



History of Tics

Suppressibility

Distractibility

Suggestibility

Variability

- Character of tics
- Frequency of tics – waxing and waning

Exacerbation with stress or excitement

Premonitory Urge

Tourette's Disorder: DSM 5

A. Both multiple motor and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently.

B. The tics may wax and wane in frequency but have persisted for more than 1 year since first tic onset.

C. Onset is before age 18 years.

D. The disturbance is not attributable to the physiological effects of a substance or another medical condition




Neurobiology of tic disorders

- Neurochemical and neuroimaging studies suggest dysfunction of the dopaminergic pathways in the cortico-striato-cortico-frontal circuitry
- Other neurotransmitter systems implicated – glutamatergic, GABA-ergic, noradrenergic, histaminergic pathways
- Highly heritable but genetically heterogenous condition
- Environmental factors may play a contributory role
 - Autoimmune dysfunction
 - Pre/perinatal adversity

Natural history of Tourette syndrome

Natural History of Tourette Syndrome



Course of Tourette Syndrome and Comorbidities in a Large Prospective Clinical Study



Camilla Groth, MD, Nanette Mol Debes, MD, PhD, Charlotte Ulrikka Rask, MD, PhD,
Theis Lange, PhD, MSc, Liselotte Skov, MSc

Objective: Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder characterized by tics and frequent comorbidities. Although tics often improve during adolescence, recent studies suggest that comorbid obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) tend to persist. This large prospective follow-up study describes the clinical course of tics and comorbidities during adolescence and the prevalence of coexisting psychopathologies.

Method: The clinical cohort was recruited at the Danish National Tourette Clinic, and data were collected at baseline ($n = 314$, age range 5–19 years) and at follow-up 6 years later ($n = 227$) to establish the persistence and severity of tics and comorbidities. During follow-up, the Development and Well-Being Assessment (DAWBA) was used to diagnose coexisting psychopathologies. Repeated measures of severity scores were modeled using mixed effects models.

Results: Tic severity declined yearly (0.8 points, CI: 0.58–1.01, on the Yale Global Tic Severity Scale [YGTSS])

during adolescence; 17.7% of participants above age 16 years had no tics, whereas 59.5% had minimal or mild tics, and 22.8% had moderate or severe tics. Similarly, significant yearly declines in severity of both OCD (0.24, CI: 0.09–0.39, on the Yale–Brown Obsessive Compulsive Scale for Adults [Y-BOCS] and Yale–Brown Obsessive Compulsive Scale for Children [CY-BOCS]) and ADHD (0.42, CI: 0.32–0.52, *DSM-IV*) were recorded. At follow-up, 63.0% of participants had comorbidities or coexistent psychopathologies, whereas 37.0% had pure TS.

Conclusion: Severity of tics, OCD, and ADHD were significantly associated with age and declined during adolescence. However, considerable comorbidities and coexisting psychopathologies persist throughout adolescence and require monitoring by clinicians.

Key words: Tourette syndrome, prospective study, clinical course, OCD, ADHD

J Am Acad Child Adolesc Psychiatry 2017;56(4):304–312.

Course of Tourette Syndrome

Tic severity declined yearly by 0.8 points on the YGTSS (0.58-1.01) during adolescence

18% of participants above age 16 years had no tics, whereas 60% had minimal or mild tics (YGTSS < 19), and 23% had moderate or severe tics

Significant yearly declines in severity of both OCD (0.24, CI: 0.09–0.39, on the CY-BOCS) and ADHD (0.42, CI: 0.32–0.52, DSM-IV) were recorded

Predictors of the Clinical Course of TS

- The strongest predictors of high tic scores, and OCD or ADHD diagnoses in adulthood were the corresponding tic, OCD and ADHD severity scores in childhood
- Being female and childhood ADHD severity predicted future emotional disorders

Quality of Life


- The presence of comorbidity has a greater impact on quality of life than tic severity in children and adults with TS
- Psychosocial domains are more affected than physical domains
- Children
 - Presence and severity of ADHD has greatest impact
- Adults
 - Presence of anxiety and depression have greatest impact



Epidemiology of Tourette syndrome and comorbidities




Prevalence: Children, School Based Studies



Prevalence of Diagnosed TS in Canada

- Data from Canadian Community Health Survey 2010/2011
- Population-based survey of Canadians age 12+
- Prevalence of diagnosed TS in adolescents was 3.33 per 1000
 - Male 6.03 per 1000
 - Female 0.48 per 1000
- Prevalence of diagnosed TS in adults was 0.66 per 1000
 - Male 0.89 per 1000
 - Female 0.44 per 1000



Sociodemographic characteristics of Canadians with TS

- Compared to the general population, Canadians with TS
 - Were less likely to attain post-secondary education
 - Had lower household income
 - Were less likely to be employed
 - If employed, were less likely to be employed full-time

The image features a dark gray background with a decorative pattern of overlapping circles in two shades of blue. A horizontal white band runs across the center of the image. The word "Comorbidity" is centered within this white band.

Comorbidity

Original Investigation

Lifetime Prevalence, Age of Risk, and Genetic Relationships of Comorbid Psychiatric Disorders in Tourette Syndrome

Matthew E. Hirschtritt, MD, MPH; Paul C. Lee, MD, MPH; David L. Pauls, PhD; Yves Dion, MD; Marco A. Grados, MD; Cornelia Illmann, PhD; Robert A. King, MD; Paul Sandor, MD; William M. McMahon, MD; Gholson J. Lyon, MD, PhD; Danielle C. Cath, MD, PhD; Roger Kurlan, MD; Mary M. Robertson, MBChB, MD, DSc(Med), FRCP, FRCPC, FRCPSych; Lisa Osiecki, BA; Jeremiah M. Scharf, MD, PhD; Carol A. Mathews, MD; for the Tourette Syndrome Association International Consortium for Genetics

Objective: to characterise the lifetime prevalence, clinical associations, ages of highest risk of psychiatric comorbidity among individuals with TS

Comorbid Psychiatric Disorders in TS

- Phenotypic data collected for genetic studies from TS-affected individuals aged 6 years +
- Recruited from tic disorder specialty clinics in North America, Great Britain and the Netherlands
- 1374 participants with TS
- 85.7% met DSM IV-TR criteria for 1 or more comorbid disorder; 57.7% met criteria for 2 or more comorbid disorders

OCD and ADHD

OCD 50% (more
common in females)

ADHD 54% (more
common in males)

30% had TS+OCD+ADHD

Other Psychiatric Comorbidities

Mood Disorders (depression, dysthymia, bipolar I and II) 30%

Anxiety Disorders (GAD, panic, agoraphobia, PTSD, SAD, social phobia, specific phobia) 36%

Disruptive Behaviour Disorders (ODD, CD) 30%

Eating Disorders (anorexia, bulimia) 2%

Psychotic disorders 1%

Substance use 6%

Comorbid Psychiatric Disorders in TS



Recommendations on the assessment and treatment of Tourette syndrome



American
Academy of
Neurology
Clinical
Practice
Guidelines

Guidelines on the assessment
and treatment of TS

Published in 2019; re-
affirmed as current in 2022

Evidence-based



Counseling recommendations: Natural History of TS

- Providing information to families about the natural history of a disorder can help inform treatment decisions
- Tics begin in childhood and demonstrate a waxing and waning course
- Peak tic severity usually occurs between the ages of 10 and 12 years, with many children experiencing an improvement in adolescence
- There is no evidence that treatment is more effective the earlier it is started.



Counseling recommendations: Natural history of TS

- 1a: Clinicians must inform patients about the natural history of tic disorders
- 1b: Clinicians must evaluate functional impairment related to tics from the perspective of the patient
- 1c: Clinicians should inform patients that watchful waiting is an acceptable treatment approach in individuals who do not experience functional impairment from their tics

Recommendations: Natural history of TS

- 1d: Clinicians may prescribe the Comprehensive Behavioural Intervention for Tics (CBIT) as an initial treatment option relative to watchful waiting for people with tics who do not experience functional impairment, if they are motivated to attempt treatment
- 1e: Physicians prescribing medications for tics must periodically re-evaluate the need for ongoing medical treatment



Psychoeducation: Teacher and Classroom

- Psychoeducation about TS with peers can result in more positive attitudes toward a person with TS
- Psychoeducation about TS with teachers can improve knowledge about the condition
- Improving peers' attitudes about and teachers' knowledge of TS may positively affect people with TS

Psychoeducation Recommendation

- 2. Clinicians should refer people with TS to resources for psychoeducation for teachers and peers
- In Alberta, you can refer them to us!

Clinical Assessment of People with Tics

Past medical history

Medication use

Developmental history

Family history

History of tics

Neurological exam

Assessment of tic severity

Secondary causes of tics



Neurodevelopmental disorders



Neurodegenerative disorders

Huntington Disease
NBIA
Neuroacanthocytosis



Postinfectious and infectious

Sydenham chorea
PANS




Structural

Vascular
Post-traumatic



Toxic/Medication-induced

Antipsychotics (tardive tics)
Psychostimulants
Antiepileptics – lamotrigine, phenytoin,
carbamazepine



Clinical Assessment of People with Tics

- Screening for comorbidities essential
 - ADHD
 - OCD
 - Generalized Anxiety Disorder
 - Oppositional Defiant Disorder
 - Mood disorders

Assessment and treatment of ADHD in people with tics

3a: Clinicians should ensure an assessment for comorbid ADHD is performed in people with tics (B)

3b: Clinicians should evaluate the burden of ADHD symptoms in people with tics (B)

3c: In people with tics and functionally impairing ADHD, clinicians should ensure appropriate ADHD treatment is provided (B)

Assessment and Treatment of OCD in people with tics



Cognitive behavioural therapy is considered first line treatment of OCD in individuals with tics disorders



4a: Clinicians should ensure an assessment for comorbid OCD is performed in people with tics (B)



4b: In people with tics and OCD, clinicians should ensure appropriate OCD treatment is provided (B)

Other Psychiatric Comorbidities

5a: Clinicians must ensure appropriate screening for anxiety, mood, and disruptive behavior disorders is performed in people with tics (A)

5b: Clinicians must inquire about suicidal thoughts and suicide attempts in people with TS and refer to appropriate resources if present (A)



Assessment of tic severity and treatment expectations

- Using validated rating scales to measure tic severity can aid the evaluation of treatment response in the clinical setting
 - Yale Global Tic Severity Scale
- While medication and behavioural therapies can result in meaningful reduction in tics, these interventions rarely result in complete cessation of tics

When should we treat tics?

- No set symptom severity threshold to determine when we should treat
- An individual choice
- Recommend that the decision be based on disability
 - Physical
 - Social
 - Emotional
- The choice of which treatment to use should be a collaborative decision between patient and clinician



Behavioural Treatments

- CBIT is a manualized treatment program consisting of habit reversal training (HRT), relaxation training, and a functional intervention to address situations that sustain or worsen tics
- People with tics receiving CBIT are more likely than those receiving psychoeducation and supportive therapy to have reduced tic severity
- A randomized controlled trial comparing behavioural and pharmacological treatments in children with tics found that behavioural therapy is as effective as pharmacological therapy

Behavioural Treatments

- 7a For people with tics who have access to CBIT, clinicians should prescribe CBIT as an initial treatment option relative to other psychosocial/behavioral interventions
- 7b For people with tics who have access to CBIT, clinicians should offer CBIT as an initial treatment option relative to medication



Antipsychotic treatment for tics

Recommendations

! Rationale

- Haloperidol, risperidone, aripiprazole, and tiapride are probably more likely than placebo to reduce tic severity
- Pimozide, ziprasidone, and metoclopramide are possibly more likely than placebo to reduce tic severity
- There is insufficient evidence to determine the relative efficacy of these drugs.
- Higher risk of drug induced movement disorders, weight gain, adverse metabolic side effects, prolactin increase and QT prolongation with both 1st and 2nd generation antipsychotics in both children and adults across psychiatric and neurological conditions

Recommendations

9a: Physicians may prescribe antipsychotic medications for the treatment of people with tics when the benefits of treatment outweigh the risk

9b: Physicians must counsel patients on the relative propensity of antipsychotic medications for extrapyramidal, hormonal and metabolic adverse effects to inform decision making on which antipsychotic should be prescribed

Recommendations

9c: Physicians prescribing antipsychotic medications for tics must prescribe the lowest effective dose of medication to decrease the risk of adverse effects

9d: Physicians prescribing antipsychotic medications for tics should monitor for drug-induced movement disorders and for metabolic and hormonal adverse effects, using evidence-based monitoring protocols

Recommendations

9e: Physicians prescribing antipsychotic medications for tics must perform ECGs and measure the QTc interval before and after starting pimozide or ziprasidone, or if antipsychotics are co-administered with other drugs that can prolong the QT interval

9f: When attempting to discontinue antipsychotic medications for tics, physicians should gradually taper medications over weeks to months to avoid withdrawal dyskinesias

Alpha agonists for the treatment of tics

Recommendations

Rationale

- In children with tics and ADHD, clonidine and guanfacine have demonstrated beneficial effects on both tics and ADHD symptoms
- Effect size for tics appears larger in children with comorbid tics and ADHD
- No evidence regarding relative efficacy of clonidine and guanfacine
- Systematic review on the use of alpha-2-adrenergics in children with ADHD demonstrated hypotension, bradycardia, and sedation with both agents, and QTc prolongation with guanfacine extended release
- Abupt withdrawal may cause rebound hypertension

Recommendations

8a: Physicians should counsel individuals with tics and comorbid ADHD that alpha-2-adrenergic agonists may provide therapeutic benefit for both conditions

8b: Physicians should prescribe alpha-2-adrenergic agonists for the treatment of people with tics when the benefits of treatment outweigh the risks

8c: Physicians must counsel patients regarding common side effects of alpha-2-adrenergic agonists, including sedation

Recommendations

- 8d: Physicians must monitor heart rate and blood pressure in all patients with tics treated with alpha-2-adrenergic agonists
- 8e: Physicians prescribing guanfacine extended release must monitor the QTc interval in patients with a history of cardiac conditions, patients taking other QTc-prolonging agents, or patients with a family history of long-QT syndrome
- 8f: Physicians discontinuing alpha-2-adrenergic agonists must gradually taper them to avoid rebound hypertension

Summary

Tourette syndrome is a common childhood onset neurodevelopmental disorder

Many children will have improvement in tic severity in late adolescence

All individuals with Tourette syndrome should be screened for comorbid psychiatric disorders

Behavioural therapies are recommended first-line for tics which cause functional impairment

There are several medications that can help decrease tic severity